HemaCare Corporation reported earnings results for the full year ended December 31, 2017. For the period, the company reported total revenues of $20.2 million, compared to $13.9 million for the year ended December 31, 2016, representing an increase of $6.3 million, or approximately 46%. The increase in Revenue was primarily derived from international expansion and improved results from key distributors and direct cell therapy customers. The company’s net income increased to $4.4 million, as compared to $0.8 million for the year ended December 31, 2016. Income before income tax benefit was $3,423,000 compared to $799,000 a year ago.